c-MET as a potential therapeutic target and biomarker in cancer
Top Cited Papers
- 1 November 2011
- journal article
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 3 (1_suppl), S21-S35
- https://doi.org/10.1177/1758834011422557
Abstract
The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), regulate multiple cellular processes that stimulate cell proliferation, invasion and angiogenesis. This review provides an overview of the evidence to support c-MET or the HGF/c-MET signaling pathway as relevant targets for personalized cancer treatment based on high frequencies of c-MET and/or HGF overexpression, activation, amplification in non-small cell lung carcinoma (NSCLC), gastric, ovarian, pancreatic, thyroid, breast, head and neck, colon and kidney carcinomas. Additionally, the current knowledge of small molecule inhibitors (tivantinib [ARQ 197]), c-MET/HGF antibodies (rilotumumab and MetMAb) and mechanisms of resistance to c-MET-targeted therapies are discussed.Keywords
This publication has 128 references indexed in Scilit:
- Plexin B1 Suppresses c-Met in Melanoma: A Role for Plexin B1 as a Tumor-Suppressor Protein through Regulation of c-MetJournal of Investigative Dermatology, 2010
- Cell Signaling by Receptor Tyrosine KinasesCell, 2010
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cellsOncogene, 2009
- Expression and mutational analysis of MET in human solid cancersGenes, Chromosomes and Cancer, 2008
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences of the United States of America, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences of the United States of America, 2007
- Plexin-B1 mutations in prostate cancerProceedings of the National Academy of Sciences of the United States of America, 2007
- Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesisProceedings of the National Academy of Sciences of the United States of America, 2006
- The Semaphorin 4D receptor controls invasive growth by coupling with MetNature, 2002